APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Neuroblastoma Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neuroblastoma Treatment Market Outlook and Growth Opportunities 2026

Report ID 174016430419 December 2025199 pages

Choose your research edition.

Industry ResearchNeuroblastoma Treatment Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroblastoma Treatment Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Neuroblastoma Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroblastoma Treatment Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroblastoma Treatment Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Neuroblastoma Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neuroblastoma Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuroblastoma Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuroblastoma Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neuroblastoma Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neuroblastoma Treatment market include Adaptimmune, CureSearch, Juno Therapeutics, Kite Pharma, NANT, Seattle Children’s, Texas Children’s, Fosun Pharmaceutical and Jiangsu Hengrui Medicine Co.,Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Neuroblastoma Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuroblastoma Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuroblastoma Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Neuroblastoma Treatment market.

Neuroblastoma Treatment Segment by Company

Adaptimmune

CureSearch

Juno Therapeutics

Kite Pharma

NANT

Seattle Children’s

Texas Children’s

Fosun Pharmaceutical

Jiangsu Hengrui Medicine Co.,Ltd.

Novartis

Sino Biopharmaceutical

Neuroblastoma Treatment Segment by Type

Vaccine Therapy

Oncolytic Virus Therapy

Chimeric Antigen Receptor T-Cell Immunotherapy

Combination Chemotherapy

Monoclonal Antibody Therapy

Neuroblastoma Treatment Segment by Application

Hospitals

Clinics

Others

Neuroblastoma Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Neuroblastoma Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Neuroblastoma Treatment key companies, revenue, market share, and recent developments.

3. To split the Neuroblastoma Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Neuroblastoma Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neuroblastoma Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Neuroblastoma Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroblastoma Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroblastoma Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroblastoma Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuroblastoma Treatment industry.

Chapter 3: Detailed analysis of Neuroblastoma Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Neuroblastoma Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Neuroblastoma Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neuroblastoma Treatment Industry Trends Table 2. Neuroblastoma Treatment Industry Drivers Table 3. Neuroblastoma Treatment Industry Opportunities and Challenges Table 4. Neuroblastoma Treatment Industry Restraints Table 5. Global Neuroblastoma Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neuroblastoma Treatment Revenue Share by Company (2021-2026) Table 7. Global Neuroblastoma Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Neuroblastoma Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Neuroblastoma Treatment Company, Product Type & Application Table 10. Global Neuroblastoma Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Neuroblastoma Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Vaccine Therapy Table 15. Significant Companies of Oncolytic Virus Therapy Table 16. Significant Companies of Chimeric Antigen Receptor T-Cell Immunotherapy Table 17. Significant Companies of Combination Chemotherapy Table 18. Significant Companies of Monoclonal Antibody Therapy Table 19. Global Neuroblastoma Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Neuroblastoma Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Neuroblastoma Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Neuroblastoma Treatment Sales Value Share by Type (2021-2026) Table 23. Global Neuroblastoma Treatment Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospitals Table 25. Significant Companies of Clinics Table 26. Significant Companies of Others Table 27. Global Neuroblastoma Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Neuroblastoma Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Neuroblastoma Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Neuroblastoma Treatment Sales Value Share by Application (2021-2026) Table 31. Global Neuroblastoma Treatment Sales Value Share by Application (2027-2032) Table 32. Global Neuroblastoma Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Neuroblastoma Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Neuroblastoma Treatment Sales Value Share by Region (2021-2026) Table 35. Global Neuroblastoma Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Neuroblastoma Treatment Sales Value Share by Region (2027-2032) Table 37. Global Neuroblastoma Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Neuroblastoma Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Neuroblastoma Treatment Sales Value Market Share by Country (2021-2026) Table 40. Global Neuroblastoma Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Neuroblastoma Treatment Sales Value Market Share by Country (2027-2032) Table 42. Adaptimmune Company Information Table 43. Adaptimmune Business Overview Table 44. Adaptimmune Neuroblastoma Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Adaptimmune Neuroblastoma Treatment Product Portfolio Table 46. Adaptimmune Recent Development Table 47. CureSearch Company Information Table 48. CureSearch Business Overview Table 49. CureSearch Neuroblastoma Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. CureSearch Neuroblastoma Treatment Product Portfolio Table 51. CureSearch Recent Development Table 52. Juno Therapeutics Company Information Table 53. Juno Therapeutics Business Overview Table 54. Juno Therapeutics Neuroblastoma Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Juno Therapeutics Neuroblastoma Treatment Product Portfolio Table 56. Juno Therapeutics Recent Development Table 57. Kite Pharma Company Information Table 58. Kite Pharma Business Overview Table 59. Kite Pharma Neuroblastoma Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Kite Pharma Neuroblastoma Treatment Product Portfolio Table 61. Kite Pharma Recent Development Table 62. NANT Company Information Table 63. NANT Business Overview Table 64. NANT Neuroblastoma Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. NANT Neuroblastoma Treatment Product Portfolio Table 66. NANT Recent Development Table 67. Seattle Children’s Company Information Table 68. Seattle Children’s Business Overview Table 69. Seattle Children’s Neuroblastoma Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Seattle Children’s Neuroblastoma Treatment Product Portfolio Table 71. Seattle Children’s Recent Development Table 72. Texas Children’s Company Information Table 73. Texas Children’s Business Overview Table 74. Texas Children’s Neuroblastoma Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Texas Children’s Neuroblastoma Treatment Product Portfolio Table 76. Texas Children’s Recent Development Table 77. Fosun Pharmaceutical Company Information Table 78. Fosun Pharmaceutical Business Overview Table 79. Fosun Pharmaceutical Neuroblastoma Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Fosun Pharmaceutical Neuroblastoma Treatment Product Portfolio Table 81. Fosun Pharmaceutical Recent Development Table 82. Jiangsu Hengrui Medicine Co.,Ltd. Company Information Table 83. Jiangsu Hengrui Medicine Co.,Ltd. Business Overview Table 84. Jiangsu Hengrui Medicine Co.,Ltd. Neuroblastoma Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Jiangsu Hengrui Medicine Co.,Ltd. Neuroblastoma Treatment Product Portfolio Table 86. Jiangsu Hengrui Medicine Co.,Ltd. Recent Development Table 87. Novartis Company Information Table 88. Novartis Business Overview Table 89. Novartis Neuroblastoma Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Novartis Neuroblastoma Treatment Product Portfolio Table 91. Novartis Recent Development Table 92. Sino Biopharmaceutical Company Information Table 93. Sino Biopharmaceutical Business Overview Table 94. Sino Biopharmaceutical Neuroblastoma Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Sino Biopharmaceutical Neuroblastoma Treatment Product Portfolio Table 96. Sino Biopharmaceutical Recent Development Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Neuroblastoma Treatment Product Image Figure 2. Global Neuroblastoma Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Neuroblastoma Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Vaccine Therapy Image Figure 8. Oncolytic Virus Therapy Image Figure 9. Chimeric Antigen Receptor T-Cell Immunotherapy Image Figure 10. Combination Chemotherapy Image Figure 11. Monoclonal Antibody Therapy Image Figure 12. Global Neuroblastoma Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Neuroblastoma Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Neuroblastoma Treatment Sales Value Share by Type (2021-2032) Figure 15. Hospitals Image Figure 16. Clinics Image Figure 17. Others Image Figure 18. Global Neuroblastoma Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Neuroblastoma Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Neuroblastoma Treatment Sales Value Share by Application (2021-2032) Figure 21. Global Neuroblastoma Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Neuroblastoma Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Neuroblastoma Treatment Sales Value (2021-2032) & (US$ Million) Figure 24. North America Neuroblastoma Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Neuroblastoma Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Neuroblastoma Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Neuroblastoma Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Neuroblastoma Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Neuroblastoma Treatment Sales Value (2021-2032) & (US$ Million) Figure 30. South America Neuroblastoma Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Neuroblastoma Treatment Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Neuroblastoma Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Neuroblastoma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Vaccine Therapy
  • Oncolytic Virus Therapy
  • Chimeric Antigen Receptor T-Cell Immunotherapy
  • Combination Chemotherapy
  • Monoclonal Antibody Therapy
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Adaptimmune
  • CureSearch
  • Juno Therapeutics
  • Kite Pharma
  • NANT
  • Seattle Children’s
  • Texas Children’s
  • Fosun Pharmaceutical
  • Jiangsu Hengrui Medicine Co.,Ltd.
  • Novartis
  • Sino Biopharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neuroblastoma Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neuroblastoma Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Neuroblastoma Treatment Market Dynamics
  1. 2.1 Neuroblastoma Treatment Industry Trends
  2. 2.2 Neuroblastoma Treatment Industry Drivers
  3. 2.3 Neuroblastoma Treatment Industry Opportunities and Challenges
  4. 2.4 Neuroblastoma Treatment Industry Restraints
3 Neuroblastoma Treatment Market by Company
  1. 3.1 Global Neuroblastoma Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Neuroblastoma Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Neuroblastoma Treatment Company Ranking (2024-2026)
  4. 3.4 Global Neuroblastoma Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Neuroblastoma Treatment Company Product Type and Application
  6. 3.6 Global Neuroblastoma Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Neuroblastoma Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Neuroblastoma Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Neuroblastoma Treatment Market by Type
  1. 4.1 Neuroblastoma Treatment Type Introduction
  2. 4.1.1 Vaccine Therapy
  3. 4.1.2 Oncolytic Virus Therapy
  4. 4.1.3 Chimeric Antigen Receptor T-Cell Immunotherapy
  5. 4.1.4 Combination Chemotherapy
  6. 4.1.5 Monoclonal Antibody Therapy
  7. 4.2 Global Neuroblastoma Treatment Sales Value by Type
  8. 4.2.1 Global Neuroblastoma Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Neuroblastoma Treatment Sales Value by Type (2021-2032)
  10. 4.2.3 Global Neuroblastoma Treatment Sales Value Share by Type (2021-2032)
5 Neuroblastoma Treatment Market by Application
  1. 5.1 Neuroblastoma Treatment Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Neuroblastoma Treatment Sales Value by Application
  6. 5.2.1 Global Neuroblastoma Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neuroblastoma Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Neuroblastoma Treatment Sales Value Share by Application (2021-2032)
6 Neuroblastoma Treatment Regional Value Analysis
  1. 6.1 Global Neuroblastoma Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neuroblastoma Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Neuroblastoma Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Neuroblastoma Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neuroblastoma Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Neuroblastoma Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Neuroblastoma Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Neuroblastoma Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Neuroblastoma Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Neuroblastoma Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Neuroblastoma Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Neuroblastoma Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Neuroblastoma Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Neuroblastoma Treatment Sales Value Share by Country, 2025 VS 2032
7 Neuroblastoma Treatment Country-level Value Analysis
  1. 7.1 Global Neuroblastoma Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neuroblastoma Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Neuroblastoma Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Neuroblastoma Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Neuroblastoma Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Neuroblastoma Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Neuroblastoma Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Adaptimmune
  2. 8.1.1 Adaptimmune Company Information
  3. 8.1.2 Adaptimmune Business Overview
  4. 8.1.3 Adaptimmune Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Adaptimmune Neuroblastoma Treatment Product Portfolio
  6. 8.1.5 Adaptimmune Recent Developments
  7. 8.2 CureSearch
  8. 8.2.1 CureSearch Company Information
  9. 8.2.2 CureSearch Business Overview
  10. 8.2.3 CureSearch Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CureSearch Neuroblastoma Treatment Product Portfolio
  12. 8.2.5 CureSearch Recent Developments
  13. 8.3 Juno Therapeutics
  14. 8.3.1 Juno Therapeutics Company Information
  15. 8.3.2 Juno Therapeutics Business Overview
  16. 8.3.3 Juno Therapeutics Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Juno Therapeutics Neuroblastoma Treatment Product Portfolio
  18. 8.3.5 Juno Therapeutics Recent Developments
  19. 8.4 Kite Pharma
  20. 8.4.1 Kite Pharma Company Information
  21. 8.4.2 Kite Pharma Business Overview
  22. 8.4.3 Kite Pharma Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Kite Pharma Neuroblastoma Treatment Product Portfolio
  24. 8.4.5 Kite Pharma Recent Developments
  25. 8.5 NANT
  26. 8.5.1 NANT Company Information
  27. 8.5.2 NANT Business Overview
  28. 8.5.3 NANT Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 NANT Neuroblastoma Treatment Product Portfolio
  30. 8.5.5 NANT Recent Developments
  31. 8.6 Seattle Children’s
  32. 8.6.1 Seattle Children’s Company Information
  33. 8.6.2 Seattle Children’s Business Overview
  34. 8.6.3 Seattle Children’s Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Seattle Children’s Neuroblastoma Treatment Product Portfolio
  36. 8.6.5 Seattle Children’s Recent Developments
  37. 8.7 Texas Children’s
  38. 8.7.1 Texas Children’s Company Information
  39. 8.7.2 Texas Children’s Business Overview
  40. 8.7.3 Texas Children’s Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Texas Children’s Neuroblastoma Treatment Product Portfolio
  42. 8.7.5 Texas Children’s Recent Developments
  43. 8.8 Fosun Pharmaceutical
  44. 8.8.1 Fosun Pharmaceutical Company Information
  45. 8.8.2 Fosun Pharmaceutical Business Overview
  46. 8.8.3 Fosun Pharmaceutical Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Fosun Pharmaceutical Neuroblastoma Treatment Product Portfolio
  48. 8.8.5 Fosun Pharmaceutical Recent Developments
  49. 8.9 Jiangsu Hengrui Medicine Co.,Ltd.
  50. 8.9.1 Jiangsu Hengrui Medicine Co.,Ltd. Company Information
  51. 8.9.2 Jiangsu Hengrui Medicine Co.,Ltd. Business Overview
  52. 8.9.3 Jiangsu Hengrui Medicine Co.,Ltd. Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Jiangsu Hengrui Medicine Co.,Ltd. Neuroblastoma Treatment Product Portfolio
  54. 8.9.5 Jiangsu Hengrui Medicine Co.,Ltd. Recent Developments
  55. 8.10 Novartis
  56. 8.10.1 Novartis Company Information
  57. 8.10.2 Novartis Business Overview
  58. 8.10.3 Novartis Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Novartis Neuroblastoma Treatment Product Portfolio
  60. 8.10.5 Novartis Recent Developments
  61. 8.11 Sino Biopharmaceutical
  62. 8.11.1 Sino Biopharmaceutical Company Information
  63. 8.11.2 Sino Biopharmaceutical Business Overview
  64. 8.11.3 Sino Biopharmaceutical Neuroblastoma Treatment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sino Biopharmaceutical Neuroblastoma Treatment Product Portfolio
  66. 8.11.5 Sino Biopharmaceutical Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst